Lexicon Pharmaceuticals to Host Fourth Quarter and Full-Year 2020 Financial Results Conference Call and Webcast on March 10, 2021

Rhea-AI Summary

Lexicon Pharmaceuticals (Nasdaq: LXRX) is set to release its fourth quarter and full-year 2020 financial results on March 10, 2021 after market close. A conference call will follow at 5:00 p.m. ET to discuss the results and provide a business update. Interested parties can join via U.S. dial-in or through an online audio webcast, which will be available for replay for 14 days. Lexicon focuses on developing innovative medicines targeting various diseases, supported by its Genome5000™ program, and has a pipeline with ongoing clinical and preclinical developments.

Positive

• Preparing to release financial results for Q4 and full-year 2020, potentially indicating growth.
• Ongoing development of promising drug candidates in various therapeutic areas.

Negative

• None.

THE WOODLANDS, Texas, March 04, 2021 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its fourth quarter and full-year 2020 financial results on Wednesday, March 10, 2021 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00 p.m. CT) that day to discuss the financial results and to provide a business update.

Dial-in Information
U.S. Dial-in Number: (888) 645-5785
International Dial-in Number:   (970) 300-1531
Conference ID: 3793713

Replay Information
U.S. Dial-in Number: (855) 859-2056
Replay International Dial-in Number: (404) 537-3406
Conference ID: 3793713

The dial-in replay will be available for 14 days following the call. An audio webcast will be available online at www.lexpharma.com/events, with a webcast replay accessible for 14 days after the call.

About Lexicon Pharmaceuticals

Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Through its Genome5000™ program, Lexicon scientists studied the role and function of nearly 5,000 genes and identified more than 100 protein targets with significant therapeutic potential in a range of diseases. Through the precise targeting of these proteins, Lexicon is pioneering the discovery and development of innovative medicines to safely and effectively treat disease. Lexicon advanced one of these medicines to market and has a pipeline of promising drug candidates in discovery and clinical and preclinical development in neuropathic pain, heart failure, diabetes and metabolism and other indications. For additional information, please visit www.lexpharma.com.

Safe Harbor Statement

This press release contains “forward-looking statements,” including statements relating to Lexicon’s financial position, long-term outlook on its business and the clinical development and therapeutic and commercial potential of its drug candidates. In addition, this press release also contains forward looking statements relating to Lexicon’s growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management’s current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including Lexicon’s ability to meet its capital requirements, successfully conduct preclinical and clinical development and obtain necessary regulatory approvals of LX9211, sotagliflozin and its other potential drug candidates on its anticipated timelines, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates. Any of these risks, uncertainties and other factors may cause Lexicon’s actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under “Risk Factors” in Lexicon’s annual report on Form 10-K for the year ended December 31, 2019, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

For Inquiries:

Chas Schultz
Executive Director, Corporate Communications and Investor Relations
Lexicon Pharmaceuticals
(281) 863-3421
cschultz@lexpharma.com

FAQ

When will Lexicon Pharmaceuticals announce its financial results?

Lexicon Pharmaceuticals will announce its financial results on March 10, 2021.

What time is the conference call for Lexicon Pharmaceuticals' financial results?

The conference call is scheduled for 5:00 p.m. ET on March 10, 2021.

How can I access the replay of Lexicon Pharmaceuticals' financial results call?

The replay can be accessed through U.S. dial-in numbers or via the audio webcast available for 14 days after the call.

What is the focus of Lexicon Pharmaceuticals' drug development?

Lexicon Pharmaceuticals focuses on developing innovative medicines for various diseases including neuropathic pain, heart failure, and diabetes.

What is the significance of the Genome5000™ program for Lexicon Pharmaceuticals?

The Genome5000™ program has been instrumental in identifying over 100 protein targets with therapeutic potential, supporting Lexicon's drug development efforts.